They prompt the pancreas to release more insulin when blood sugar is high, which helps move sugar from the bloodstream into the bodys cells, where it can be used for energy, thereby helping to lower blood sugar levels
These differences were first illustrated in LEAD and AWARD, the phase 3 clinical trial programs for liraglutide and dulaglutide, respectively (141, 142)
stated that it and Novo Nordisk Pharma Ltd
New 2025 clinical research shows that GLP-1 medications like Ozempic (semaglutide) may significantly reduce alcohol cravings and heavy drinking
However, fewer side effects does not automatically mean equally effective results. Label-guided slow titration already exists to balance both
Potential Side Effects and Limited Long-Term Safety Data Potential side effects and limited long-term safety data are restraining the growth of the GLP-1 targeted peptide weight loss drugs market